STOP-PKD Study (SGLT2-Inhibitors)
Written on . Posted in News and Events.
The STOP-PKD study investigates for the first time the safety and efficacy of SGLT2-inhibitors in ADPKD patients. Prof. Dr. Roman-Ulrich Müller, Professor of Translational Nephrology and spokesperson for the Center for Rare and Hereditary Kidney Diseases, has received funding from the German Research Foundation (DFG) for a multicenter drug study.
Coordinated with Dr. Philipp Scherrer, the STOP-PKD study examines SGLT2-inhibitor use in patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disease causing large cystic kidneys and progressive loss of kidney function. Affected individuals typically need renal replacement therapy (dialysis, kidney transplantation) by age 50-60.
SGLT2-inhibitors are now essential in medicine, providing significant prognostic improvement in chronic kidney disease, diabetes, and heart failure. Previously, ADPKD patients were excluded from approval studies for chronic kidney disease treatment. Given limited treatment options for ADPKD, the STOP-PKD study aims to investigate SGLT2-inhibitor safety and efficacy in adults with ADPKD.
The investigator-initiated study is designed as a randomized, placebo-controlled, double-blind, multicenter study conducted to the highest quality standards in 18 German and six European study centers. The DFG supports the six-year project with over three million euros in the first three years, with continuation funding for the next three years already planned.